Compile Data Set for Download or QSAR
Report error Found 2763 Enz. Inhib. hit(s) with Target = 'Envelope glycoprotein gp160'
TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM50002692(1-((2R,4S,5S)-4-Azido-5-hydroxymethyl-tetrahydro-f...)
Affinity DataEC50:  3nMAssay Description:The in vitro antiviral activity profile for CMX157 was evaluated for cell-type effects and HIV strain effects. It is active against all major subtype...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM77141(CMX157 ion)
Affinity DataEC50: <30nMAssay Description:The in vitro antiviral activity profile for CMX157 was evaluated for cell-type effects and HIV strain effects. It is active against all major subtype...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM77097(CMX157-210)
Affinity DataEC50: >1.00E+4nMAssay Description:The in vitro antiviral activity profile for CMX157 was evaluated for cell-type effects and HIV strain effects. It is active against all major subtype...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM77105(CMX157-211)
Affinity DataEC50: >1.00E+4nMAssay Description:The in vitro antiviral activity profile for CMX157 was evaluated for cell-type effects and HIV strain effects. It is active against all major subtype...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM77108(CMX157-220)
Affinity DataEC50: >1.00E+4nMAssay Description:The in vitro antiviral activity profile for CMX157 was evaluated for cell-type effects and HIV strain effects. It is active against all major subtype...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM235034(2-(((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-...)
Affinity DataEC50:  80nMAssay Description:MT-2 cells and 293T cells were obtained from the NIH AIDS Research and Reference Reagent Program. MT-2 cells were propagated in RPMI 1640 media suppl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM235035(4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13 aR,13bR)-3a-((...)
Affinity DataEC50: <100nMAssay Description:MT-2 cells and 293T cells were obtained from the NIH AIDS Research and Reference Reagent Program. MT-2 cells were propagated in RPMI 1640 media suppl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM235036(4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,...)
Affinity DataEC50: >100nMAssay Description:MT-2 cells and 293T cells were obtained from the NIH AIDS Research and Reference Reagent Program. MT-2 cells were propagated in RPMI 1640 media suppl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM235037(4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13 aR,13bR)-3a-(5...)
Affinity DataEC50: >100nMAssay Description:MT-2 cells and 293T cells were obtained from the NIH AIDS Research and Reference Reagent Program. MT-2 cells were propagated in RPMI 1640 media suppl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM235038(4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,...)
Affinity DataEC50: >100nMAssay Description:MT-2 cells and 293T cells were obtained from the NIH AIDS Research and Reference Reagent Program. MT-2 cells were propagated in RPMI 1640 media suppl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM235039(4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(1-...)
Affinity DataEC50: >100nMAssay Description:MT-2 cells and 293T cells were obtained from the NIH AIDS Research and Reference Reagent Program. MT-2 cells were propagated in RPMI 1640 media suppl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM235040(4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,...)
Affinity DataEC50: >100nMAssay Description:MT-2 cells and 293T cells were obtained from the NIH AIDS Research and Reference Reagent Program. MT-2 cells were propagated in RPMI 1640 media suppl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271359(4-[(1R)-1- [(1R,2R,5R,10S,13R,14R, 17S,19R)-17-[(3...)
Affinity DataEC50:  41.1nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271359(4-[(1R)-1- [(1R,2R,5R,10S,13R,14R, 17S,19R)-17-[(3...)
Affinity DataEC50:  34.6nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271365(4-[(1R)-1- [(1R,2R,5R,10S,13R,14R, 17S,19R)-17-[(3...)
Affinity DataEC50:  5.20nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271365(4-[(1R)-1- [(1R,2R,5R,10S,13R,14R, 17S,19R)-17-[(3...)
Affinity DataEC50:  4.70nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271386(4-[(1S)-1- [(1R,2R,5R,10S,13R,14R, 17S,19R)-17-[(3...)
Affinity DataEC50:  61.7nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271386(4-[(1S)-1- [(1R,2R,5R,10S,13R,14R, 17S,19R)-17-[(3...)
Affinity DataEC50:  243nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271387(4-[(1S)-1- [(1R,2R,5R,10S,13R,14R, 17S,19R)-17-[(3...)
Affinity DataEC50:  10.1nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271387(4-[(1S)-1- [(1R,2R,5R,10S,13R,14R, 17S,19R)-17-[(3...)
Affinity DataEC50:  9.30nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271388(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{[(4- ch...)
Affinity DataEC50:  2.60nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271388(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{[(4- ch...)
Affinity DataEC50:  3.20nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271389(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[2- (benzyl...)
Affinity DataEC50:  0.5nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271389(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[2- (benzyl...)
Affinity DataEC50:  3.80nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271390(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{[(3- ch...)
Affinity DataEC50:  6.10nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271390(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{[(3- ch...)
Affinity DataEC50:  23.1nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271391(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{[(3- ch...)
Affinity DataEC50:  5.90nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271391(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{[(3- ch...)
Affinity DataEC50:  14.3nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271392(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{[1-(4- ...)
Affinity DataEC50:  12.3nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271392(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{[1-(4- ...)
Affinity DataEC50:  13.5nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271393(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{[(4- ch...)
Affinity DataEC50:  2.30nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271393(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{[(4- ch...)
Affinity DataEC50:  2.40nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271394(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{[1-(4- ...)
Affinity DataEC50:  6.30nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271394(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{[1-(4- ...)
Affinity DataEC50:  6.70nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271395(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{[(4- ch...)
Affinity DataEC50:  4.5nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271395(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{[(4- ch...)
Affinity DataEC50:  5.10nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271396(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{N-[(4- ...)
Affinity DataEC50:  1.60nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271396(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{N-[(4- ...)
Affinity DataEC50:  2.10nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271397(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  2.10nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271397(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  3.60nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271398(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-2- {[...)
Affinity DataEC50:  6.90nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271398(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-2- {[...)
Affinity DataEC50:  31.1nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271399(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-2- {[...)
Affinity DataEC50:  11nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271399(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-2- {[...)
Affinity DataEC50:  7.60nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271400(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-1- (a...)
Affinity DataEC50:  8.70nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271400(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-1- (a...)
Affinity DataEC50:  29.2nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271401(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  0.800nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271401(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  0.700nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271402(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-2- {[...)
Affinity DataEC50:  3.90nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271402(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-2- {[...)
Affinity DataEC50:  4.10nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

Displayed 1 to 50 (of 2763 total ) | Next | Last >>
Jump to: